A Comparative Trial of a Minimal-invasive Technique Versus Open Arthrodesis in the Treatment of Midfoot Arthritis

Osteoarthritis Clinical Trial

Official title:

Can Reverse Oblique Distal Minimal-invasive Osteotomies Replace Arthrodesis of the Tarsometatarsal Joints? - a Prospective, Comparative Trial of 50 Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04894578
• Other study ID #: 2020-00916
• Status: Recruiting
• Phase: N/A
• Start date: May 14, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2021
• Source: Kantonsspital Baden
• Contact: Karim Eid, PD Dr. med.
• Phone: 0564863062
• Email: karim.eid[@]ksb.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Group A: Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy Group B: Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints

Description:

Midfoot arthritis is a common condition leading to disabling chronic foot pain that affects activities of daily living. The causes can be primary osteoarthritis (OA), inflammatory or post-traumatic. We are looking at OA of the lesser (second and/or third) tarsometatarasal joints (TMTJ). Orthotics, customised shoes or steroid injections are options to treat this condition nonoperatively. If these measures fail, arthrodesis of the arthritic joints represents the standard procedure to surgical treatment. Generally, the results of this procedure are at a satisfactory level for the patients, nevertheless, there is a relevant amount of patients with residual pain, lack of a normal foot appearance, and the need for unplanned surgery or use of orthotics postoperatively. Furthermore, patients undergoing an arthrodesis of the lesser TMTJ usually have to stay in hospital for 4-7 days. Postoperatively, patients are only allowed to partially weightbear for at least 6 weeks and need a cast for six weeks as well. During that time thrombosis prophylaxis is administered for about 6 weeks.

The conventional distal minimal-invasive metatarsal osteotomy (DMMO) is an accepted technique for metatarsal osteotomies. Recently, Schneider et al. presented results of a modification of the conventional DMMO, the reverse DMMO to treat OA of the lesser TMTJ, thus representing an alternative treatment to arthrodesis. The procedure has many benefits. It allows outpatient care, an immobilisation in a cast is not necessary. Instead, patients have to wear a flat postoperative shoe for 2-3 weeks and are allowed to fully weightbear from day one after surgery. Therefore, thrombosis prophylaxis is not necessary unless there are specific risk factors.

However, while the arthrodesis directly addresses the arthritic joints, the R-DMMO alters the ground reaction force of the metatarsal head leading to less stress at the level of the TMTJ, but the arthritic joint itself is not approached. Still, the results presented by Schneider et al. are promising. Since there was no group to compare the treatment with, the small sample size, and a retrospective design, we would like to prospectively compare these two surgical procedures directly in order to find out whether or not the R-DMMO can be recommended as a standard procedure for OA of the lesser TMTJ at a much more convenient level for patients regarding the whole perioperative protocol. No vulnerable population is included. The scientific value is remarkable since this would be the first study to examine this matter and we are able to provide a high level of evidence due to the prospective-randomised and comparative design of the study. All legal requirements will be fulfilled and the ethical standards are guaranteed.

Both procedures have been described and the technique of the DMMO itself is not new, but its modification (R-DMMO) represents a new approach for this condition. Both procedures are reliable and safe, which is why the risk category of the study is A according to ClinO, Art. 61.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients older than 18 years

• Midfoot arthritis of lesser TMTJ (second, third, rarely fourth and fifth) with ongoing disabling pain

• Able to give informed consent as documented by signature

• failed conservative treatment for a period of at least 3 months (CSI injections and/or orthotic devices)

Exclusion Criteria:

• Concomitant fusion of 1st TMTJ

• Patients younger than 18 years

• Contraindication to undergo surgery or general anaesthesia

• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

• pregnancy

Related Conditions & MeSH terms

• Foot
• Osteoarthritis
• Osteotomy

Intervention

Procedure:
• reverse distal metatarsal minimal-invasive osteotomy
minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
• tarsometatarsal fusion
open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints

Locations

Country	Name	City	State
Switzerland	Kantonsspital Baden	Baden	Aargau

Sponsors (1)

Lead Sponsor	Collaborator
Kantonsspital Baden

Country where clinical trial is conducted

Switzerland, 

References & Publications (3)

Gougoulias N, Lampridis V. Midfoot arthrodesis. Foot Ankle Surg. 2016 Mar;22(1):17-25. doi: 10.1016/j.fas.2015.04.004. Epub 2015 Apr 24. — View Citation

Laffenêtre O, Perera A. Distal Minimally Invasive Metatarsal Osteotomy ("DMMO" Procedure). Foot Ankle Clin. 2019 Dec;24(4):615-625. doi: 10.1016/j.fcl.2019.08.011. Review. — View Citation

Schneider TE, Varrall CR, Malhotra K. Early results of minimally invasive, reverse-oblique, distal metaphyseal metatarsal osteotomy (R-DMMO) for arthritis of the lesser tarsometatarsal joints - A retrospective case series. Foot (Edinb). 2020 Jun;43:101652. doi: 10.1016/j.foot.2019.10.007. Epub 2019 Oct 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Outcome using a patient related outcome measure, the FAAM score (Validated Foot and Ankle Ability Measure). The score is a self-report outcome instrument developed to assess physical function. The change between the time points is measured.	FAAM score, the highest score is 100, indicating the best possible outcome	6 weeks, 3 months, 6 months, 12 and 24 months post surgery
Secondary	Duration of procedure	Duration of procedure (in minutes from first incision until wound is closed)	through study completion, an average of 2 years
Secondary	Length of hospital stay	Length of hospital stay in days	through study completion, an average of 2 years
Secondary	Visual Analogue Scale (VAS) score. It is a measurement instrument for the amount of pain that a patient feels. The score is assessed preoperatively and the change between the time points is measured.	Pain score (scale 0-10, where 10 is the maximum pain)	6 weeks, 3 months, 6 months, 12 and 24 months post surgery
Secondary	Radiological union by evaluating conventional X-Ray. Preoperative X-Rays and postoperative X-Rays are comparted and the change in union in terms of bone densitiy is assessed postoperatively.	Union of bone on conventional X-Ray in two planes (dorsoplantar and lateral views)	6 weeks, 3 months, 6 months, 12 and 24 months post surgery
Secondary	Complications	Identifying minor and major complications of the procedure (e.g. infections)	6 weeks, 3 months, 6 months, 12 and 24 months post surgery